GE Healthcare announces the launch of Sensor Chip CM7. Designed for use with GE Healthcare’s Biacore systems, Sensor Chip CM7 has the high immobilization capacity required to support fragment-based screening of small molecules.
Sensor Chip CM7 offers improved screening data quality as it delivers high signal-to-noise ratios. In addition, Sensor Chip CM7 gives improved detection in cases where immobilization levels are unfavorable, such as low concentration of target protein or a target protein that is sensitive to optimal immobilization conditions.
Sensor Chip CM7 has a carboxymethylated dextran matrix covalently attached to gold film, with a higher degree of carboxylation and a denser matrix compared to Sensor Chip CM5. It is capable of binding proteins, nucleic acids, carbohydrates, or small molecules to carboxyl groups on the sensor surface via –NH2, -SH, -CHO, -OH, or -COOH. The analyte is then passed over the surface and any binding is detected by the Biacore system.
Filed Under: Drug Discovery